Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma

BACKGROUND: In the phase III METEOR trial, tyrosine kinase inhibitor cabozantinib significantly improved progression-free survival (PFS), objective response rate (ORR), and overall survival compared to everolimus in patients with advanced renal cell carcinoma (RCC) who had received prior VEGFR inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacy, Steven, Nielsen, Jace, Yang, Bei, Miles, Dale, Nguyen, Linh, Hutmacher, Matt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973957/
https://www.ncbi.nlm.nih.gov/pubmed/29667066
http://dx.doi.org/10.1007/s00280-018-3579-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973957/
https://www.ncbi.nlm.nih.gov/pubmed/29667066
http://dx.doi.org/10.1007/s00280-018-3579-7

Ejemplares similares